loading page

“Unplanned breast-conserving surgery after systemic therapy in locally advanced breast cancer: the results of level II oncoplastic techniques”
  • mehmet gulcelik,
  • Lütfi Doğan
mehmet gulcelik
Universty of health sciences Gulhane medical school

Corresponding Author:[email protected]

Author Profile
Lütfi Doğan
Dr Abdurrahman Yurtaslan Onkoloji Eğitim ve Araştırma Hastanesi
Author Profile

Abstract

BACKGROUND: In patients with breast cancer for whom neoadjuvant chemotherapy (NAC) is planned, it is recommended to mark the primary tumor before treatment (planned surgery). However, surgeons may have to perform breast-conserving surgery on patients whose tumors are not marked (unplanned surgery). This study focused on the results obtained with planned and unplanned level II oncoplastic surgery (OPS) techniques applied to patients after NAC. METHODS: Patient groups who underwent planned, unplanned OPS and mastectomy after NAC were compared. Surgical margin status, re-operation and re-excision requirements, ipsilateral breast tumor recurrence (IBTR) and axillary recurrence rates recorded. Long-term local recurrence-free survival (LRFS), disease-free survival and overall survival were evaluated. RESULTS: There was no significant difference between the planned and unplanned OPS groups in terms of surgical margin status, re-excision requirement, and mastectomy rates. During an average follow-up period of 43 months, 5.3% and 4% of the patients in the planned OPS group developed IBTR and axillary recurrence, respectively, whereas these rates were 6.6% and 5.3% in the unplanned OPS group. In the mastectomy group, the rates of IBTR and axillary recurrence were found to be 4.1% and 3.8%, respectively. There was no significant difference between the three groups in terms of IBTR (p: 0.06) and axillary recurrence (p: 0.08) rates. CONCLUSION: Breast conserving surgery can be applied using level II OPS techniques with the post-NAC radiological examination and marking even if primary tumor marking is not done in the pre-NAC period.
02 Feb 2021Submitted to International Journal of Clinical Practice
02 Feb 2021Submission Checks Completed
02 Feb 2021Assigned to Editor
11 Feb 2021Reviewer(s) Assigned
05 Mar 2021Review(s) Completed, Editorial Evaluation Pending
20 Mar 20211st Revision Received
20 Mar 2021Submission Checks Completed
20 Mar 2021Assigned to Editor
16 Apr 2021Reviewer(s) Assigned
18 Apr 2021Review(s) Completed, Editorial Evaluation Pending
19 Apr 2021Editorial Decision: Accept